“Significant inventions often occur within academic settings and lead to new insights into how to care for, manage or diagnose disease, but they can stagnate because of the time and resources needed to move them to broader validation,” said PatientsLikeMe Co-Founder and Chairman
Based at the
"A renewed focus on phenotypes and a democratic, open approach to measuring wellness and disease will enable a new partnership between individuals and their physicians," said Dennis Ausiello, M.D., CATCH’s Co-Founder and Director. "This collaboration with PatientsLikeMe will ensure our work is tested and validated in the real world and brought to the discovery and development process far sooner than was ever before possible.”
The collaboration will initially focus on integrating the PatientsLikeMe virtual registry with several of CATCH’s clinical research initiatives. Both CATCH and PatientsLikeMe researchers will combine data and develop models for rapid translation from the lab to the bedside to the large-scale vertical network. PatientsLikeMe will also bring its tools for patient engagement and feedback into the clinic for the first time, to help create a shared learning environment between leading doctors and a broad group of patients working together to improve disease care, outcomes and value.
PatientsLikeMe® (www.patientslikeme.com) is a patient network that improves lives and a real-time research platform that advances medicine. Through the network, patients connect with others who have the same disease or condition and track and share their own experiences. In the process, they generate data about the real-world nature of disease that help researchers, pharmaceutical companies, regulators, providers, and nonprofits develop more effective products, services and care. With more than 250,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 50 peer-reviewed research studies. Visit us at www.patientslikeme.com or follow us via our blog, Twitter or Facebook.